Expression of Snail, Zeb2 and Sfrp1 are altered in transdifferentiated cells. (A) QPCR expression of Snail, Zeb2 and Sfrp1 in pTD cells and tumours relative to CDβGeo. (B) QPCR expression of Snail, Zeb2 and Sfrp1 relative to CDβGeo cells in TM40A cells with wild type p53 or p53 knock-down maintained in control media or TGFβ media. *p < 0.05; **p < 0.01. (C) Changes in expression of Snail, Zeb2 and Sfrp1 relative to CDβGeo cells (*p < 0.05, **p < 0.01) and relative to pTD cells (#p < 0.05, ##p < 0.01) after 24 hour treatment with TGFβ inhibitor LY364947 and 48 hours after withdrawal of LY364947 demonstrate that autocrine production of TGFβ2 may support persistent EMT.